The predictability of renin–angiotensin–aldosterone system factors for clinical outcome in patients with acute decompensated heart failure

Yasuki Nakada(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Akira Funada(National Cerebral and Cardiovascular Center), Satoshi Yasuda(Tohoku University), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Hisao Ogawa(Kumamoto University Hospital), Akemi Yoshida(National Cerebral and Cardiovascular Center), Makoto Amaki(National Cerebral and Cardiovascular Center), Takuya Hasegawa(National Cerebral and Cardiovascular Center), Hiroyuki Takahama(Tohoku University), Takahiro Ohara(Tohoku Medical and Pharmaceutical University), Yasuo Sugano(keiyu Hospital)
Heart and Vessels
May 11, 2015
10.1007/s00380-015-0688-7
Cited by 20

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755